Cushing's Syndrome and Disease

• Chronic hypercortisolemia and its metabolic consequences: Excess cortisol drives a catabolic state through multiple mechanisms. At the cellular level, glucocorticoids bind to glucocorticoid receptors (GR) located in the cytoplasm; this ligand-receptor complex translocates to the nucleus where it modulates gene transcription by binding glucocorticoid response elements (GREs) to upregulate catabolic genes and suppress anabolic processes. Glucocorticoid excess promotes proteolysis in muscle through increased ubiquitin-proteasome system activity, decreases amino acid uptake by skeletal muscle, and stimulates hepatic gluconeogenesis (contributing to hyperglycemia and impaired glucose tolerance or overt diabetes mellitus). Simultaneously, cortisol antagonizes insulin action at the cellular level by impairing GLUT4 translocation and reducing insulin secretion by pancreatic beta cells. Lipid metabolism is profoundly altered: cortisol increases lipolysis in peripheral adipose tissue while simultaneously promoting lipogenesis in visceral fat depots through a combination of increased free fatty acid mobilization and redistribution of adipose tissue via altered expression of peroxisome proliferator-activated receptor-γ (PPAR-γ). This accounts for the classic "truncal obesity with peripheral wasting" phenotype. The sustained elevation of free cortisol increases hepatic VLDL production and impairs LDL catabolism, resulting in dyslipidemia. Additionally, cortisol decreases bone formation by suppressing osteoblast differentiation and function (partly through reduced IGF-1 and increased IL-6), while simultaneously increasing bone resorption through effects on osteoclast activation, leading to accelerated osteoporosis.

• Cardiovascular and electrolyte effects: Cortisol excess causes hypertension through multiple intersecting mechanisms. Glucocorticoids increase vascular reactivity to catecholamines by upregulating alpha-adrenergic receptors on vascular smooth muscle, enhance endothelial expression of vasoconstrictive molecules (including endothelin-1), increase angiotensinogen production in the liver (amplifying the renin-angiotensin-aldosterone system), and activate mineralocorticoid receptors (albeit weakly—cortisol becomes an agonist at MR when 11β-hydroxysteroid dehydrogenase type 2 is overwhelmed), promoting sodium retention and potassium wasting. These combined effects result in plasma volume expansion and increased peripheral vascular resistance. Furthermore, chronic cortisol excess promotes atherosclerosis through pro-inflammatory effects (upregulation of IL-6, TNF-α, and adhesion molecules), impaired endothelial function, and adverse effects on lipid metabolism. Glucocorticoid excess also increases coagulability through upregulation of tissue factor and increased platelet reactivity. The net result is a marked increase in cardiovascular morbidity and mortality, with hypertension occurring in 70-80% of Cushing's syndrome patients and myocardial infarction or stroke being leading causes of death in untreated disease.

• Immunosuppression and increased infection susceptibility: Excess glucocorticoids suppress virtually all aspects of innate and adaptive immunity. Cortisol inhibits the differentiation and proliferation of T lymphocytes (particularly Th1 and Th17 cells) and suppresses IL-2 production, leading to reduced cell-mediated immunity; B lymphocyte function is impaired, reducing antibody-mediated responses. Glucocorticoids decrease neutrophil chemotaxis and impair oxidative burst capacity, reducing microbicidal activity. Macrophage function is suppressed through decreased antigen presentation and cytokine production. These immune effects substantially increase susceptibility to both common bacterial infections and opportunistic pathogens (including Pneumocystis jirovecii, Mycobacterium tuberculosis, fungal infections, and cytomegalovirus), representing a major source of morbidity and mortality in severe Cushing's syndrome.

• Psychiatric and neurological manifestations: The CNS effects of chronic hypercortisolemia are substantial and multifaceted. Cortisol crosses the blood-brain barrier readily and binds to both glucocorticoid receptors and mineralocorticoid receptors (MR) in the hippocampus, prefrontal cortex, and amygdala—regions critical for mood, memory, and emotional processing. Excess cortisol induces hippocampal atrophy through oxidative stress, excitotoxicity, and reduced neurotrophic factor expression (particularly BDNF); this structural change correlates with cognitive impairment and mood disturbances. Chronic glucocorticoid excess alters monoamine metabolism (reducing serotonergic and dopaminergic neurotransmission), hyperactivates the amygdala (contributing to anxiety and emotional lability), and impairs the normal glucocorticoid feedback regulation of the HPA axis itself, creating a maladaptive loop. These changes drive the high prevalence of depression (occurring in 50-80% of patients), anxiety disorders, emotional lability, and cognitive dysfunction observed in Cushing's syndrome. Psychosis can occur in severe cases. The psychiatric symptoms often persist for months to years after successful treatment, reflecting the time required for structural and functional CNS recovery.

• Skin manifestations and connective tissue effects: The distinctive skin findings in Cushing's syndrome reflect underlying collagen degradation and altered dermal structure from prolonged glucocorticoid excess. Purple striae (stretch marks) result from cortisol-induced collagen breakdown and loss of dermal elasticity combined with mechanical stretching from rapid weight redistribution; striae in Cushing's syndrome are notably wider (>1 cm) and more deeply pigmented than typical stretch marks in adolescents. Glucocorticoids inhibit dermal fibroblast proliferation and collagen synthesis while simultaneously increasing collagenase expression, leading to thin, fragile skin with poor wound healing. Skin atrophy contributes to easy bruising from minor trauma, and the capillary fragility underlies the characteristic ecchymoses. Additionally, impaired cell-mediated immunity increases susceptibility to fungal infections; hirsutism results from elevated adrenal androgens, while acne similarly reflects androgenic effects. The skin changes reflect systemic connective tissue fragility, accounting for the increased incidence of spontaneous fractures from osteoporosis.

• ACTH-secreting pituitary adenoma (Cushing's disease): This is the most common endogenous cause, accounting for approximately 70-80% of Cushing's syndrome cases. These adenomas typically arise as clonal expansions of corticotroph cells; molecular pathogenesis frequently involves USP8 mutations (~40% of cases, particularly common in microadenomas), which impair ubiquitin-mediated degradation of BMP type II receptor and enhance BMP signaling, promoting corticotroph proliferation. Other mutations include PRKAR1A mutations (associated with familial disease and Carney complex in rare cases) and loss of MKRN3 tumor suppression. Most pituitary corticotroph adenomas are microadenomas (<10 mm); macroadenomas (>10 mm) occur in approximately 20% of cases and often present with mass effects including headache, visual field defects, and other pituitary hormone deficiencies. Males and females are equally affected. Risk factors for pituitary adenomas include prior pituitary irradiation (though this more commonly causes gonadotropinomas) and familial adenomatous polyposis (FAP) associated with germline APC mutations, which increase risk of pituitary adenomas and other neuroendocrine tumors.

• Ectopic ACTH production: In 10-15% of endogenous Cushing's syndrome cases, ACTH is secreted from a non-pituitary source, most commonly small-cell lung cancer (SCLC), which accounts for approximately 50-60% of ectopic ACTH cases. Other common sources include carcinoid tumors (thymic, bronchial, gastric, or pulmonary origin), pheochromocytoma, medullary thyroid cancer, and pancreatic neuroendocrine tumors. Ectopic ACTH syndrome typically presents more acutely and with greater severity than Cushing's disease, often associated with hypokalemic metabolic alkalosis, glucose intolerance, and visible weakness due to the higher absolute cortisol levels; psychiatric symptoms are often less prominent despite severe hypercortisolemia. The underlying malignancy frequently becomes clinically apparent within 2-5 years of Cushing's syndrome diagnosis. Ectopic CRH production is rare (<1% of cases) but can originate from neuroendocrine tumors or carcinoids.

• Primary adrenocortical causes (ACTH-independent): Adrenocortical adenomas account for 10-15% of Cushing's syndrome cases and typically present with mild hypercortisolemia; they are more common in women and increase in prevalence with age. These are usually unilateral tumors <4 cm. Adrenocortical carcinoma is a rare cause (1-2% of cases) but should be suspected when cortisol excess is severe, an adrenal mass >4 cm is present, and heterogeneity or necrosis is evident on imaging; these are highly aggressive tumors with poor prognosis. Primary bilateral adrenal hyperplasia (PBAH), formerly called "primary pigmented nodular adrenocortical disease (PPNAD)" or "macronodular hyperplasia" depending on morphology, accounts for 2-3% of Cushing's syndrome cases and is often familial; PPNAD is associated with PRKAR1A mutations (carciney complex) and sometimes CNC1 mutations. Macronodular hyperplasia is associated with aberrant expression of ectopic hormone receptors or their ligands (including GIP receptors, vasopressin receptors, LH receptors, or serotonin receptors), leading to ACTH-independent cortisol secretion. Genetic predisposition to PBAH includes germline PRKAR1A, PDE11A, PDE8B, and ARMC5 mutations.

• Iatrogenic (exogenous) Cushing's syndrome: This is the most common overall cause of Cushing's syndrome and results from prolonged therapeutic glucocorticoid administration. Risk increases with cumulative dose and duration of therapy; doses >7.5 mg of prednisone daily for >2 weeks carry substantial risk. Any glucocorticoid preparation (systemic or even topical/inhaled when used in high doses or for prolonged periods) can cause iatrogenic Cushing's syndrome. Common clinical scenarios include treatment of inflammatory/autoimmune conditions (polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, SLE), respiratory diseases (COPD, asthma), malignancy, and post-transplant immunosuppression. The severity correlates with dose and duration. Unlike endogenous Cushing's syndrome, the diagnosis is straightforward given the known exogenous glucocorticoid exposure.

• Alcohol-associated Cushing's syndrome: Chronic alcohol abuse can induce a pseudo-Cushing's syndrome through altered HPA axis regulation, elevated midnight salivary cortisol, and reduced dexamethasone suppression, mimicking Cushing's syndrome; however, true pathologic cortisol hypersecretion is typically mild, and the abnormalities normalize with alcohol cessation. This is an important diagnostic consideration because alcoholics can present with stigmata superficially resembling Cushing's syndrome (central obesity, proximal weakness, hypertension).

• Central/truncal obesity with peripheral wasting: This is one of the most characteristic and diagnostically important signs. Redistribution of adipose tissue occurs due to differential effects of cortisol on regional adipose depots—increased lipolysis in subcutaneous extremity fat combined with enhanced lipogenesis and hypertrophy in intra-abdominal visceral fat. Patients develop a distinctive appearance with central adiposity, supraclavicular fat pads ("buffalo hump" or dorsocervical fat pad hypertrophy), and prominent suprapubic fat, contrasting sharply with thin extremities, thin forearms, and diminished muscle bulk. This central obesity pattern distinguishes Cushing's syndrome from simple obesity, where fat distribution is more generalized. The rapidity of weight gain (often 10-20+ lbs over months) is notable.

• Muscle weakness and wasting (proximal myopathy): Severe proximal muscle weakness is a hallmark of Cushing's syndrome and often brings patients to medical attention. The pathophysiology involves cortisol-induced proteolysis through multiple mechanisms—upregulation of ubiquitin-proteasome system activity in muscle, increased myostatin expression (inhibiting myogenic differentiation), suppressed amino acid uptake, and antagonism of IGF-1/insulin anabolic signaling. Patients report difficulty rising from a chair, climbing stairs, or lifting objects; knee and hip extensors are particularly affected. Muscle biopsy shows type II (fast-twitch) fiber atrophy. The weakness can be profound in severe or ectopic ACTH syndrome, occasionally progressing to rhabdomyolysis in extreme cases. Hypokalemic paralysis can occur, particularly with ectopic ACTH syndrome, when severe hypokalemia (due to mineralocorticoid effects and urinary wasting) compromises muscle membrane potential.

• Hypertension and cardiovascular manifestations: Elevated blood pressure occurs in 70-80% of Cushing's syndrome patients and results from the multiple mechanisms described in pathophysiology (increased vascular reactivity, sodium/fluid retention, activation of RAAS and endothelin, endothelial dysfunction). Hypertension is often resistant to conventional therapy and improves only with treatment of the underlying Cushing's syndrome. Cardiovascular complications include myocardial infarction, ischemic and hemorrhagic stroke, left ventricular hypertrophy from chronic hypertension, and

• 1 mg overnight dexamethasone suppression test: dexamethasone at bedtime, serum cortisol at 8 a.m.; failure to suppress below roughly 1.8 mcg/dL is abnormal. False positives arise from estrogen/OCP (raises cortisol-binding globulin), CYP3A4 inducers, and malabsorption.
• Late-night salivary cortisol (two separate nights): detects loss of the normal nocturnal nadir, the earliest physiologic abnormality.
• 24-hour urinary free cortisol (two collections): measures unbound cortisol; unreliable when creatinine clearance is reduced.
• Pseudo-Cushing states — alcohol use disorder, severe depression, poorly controlled diabetes, obesity — are the classic confounders; the dexamethasone–CRH test or repeat testing after abstinence clarifies.

Step 2 — the single best next step once hypercortisolism is confirmed: plasma ACTH.

• Suppressed ACTH (roughly <5 pg/mL) = ACTH-independent → adrenal CT; a mass >4 cm with heterogeneity or necrosis suggests adrenocortical carcinoma.
• Normal or elevated ACTH (roughly >20 pg/mL) = ACTH-dependent → pituitary MRI with contrast plus dynamic testing.

Step 3 — pituitary versus ectopic

• High-dose (8 mg) dexamethasone suppression and CRH stimulation: corticotroph adenomas retain partial feedback and CRH responsiveness, so cortisol falls substantially and ACTH rises; ectopic tumors do neither.
• Inferior petrosal sinus sampling is the gold standard when MRI shows no adenoma or a lesion under ~6 mm, or when dynamic tests conflict — a central-to-peripheral ACTH gradient of ≥2 at baseline or ≥3 after CRH localizes disease to the pituitary.
• Ectopic search: CT chest/abdomen and somatostatin-receptor imaging (Ga-68 DOTATATE) for small-cell lung cancer and carcinoids.

Definitive therapy is surgical (Endocrine Society Clinical Practice Guideline on Treatment of Cushing's Syndrome)

• Cushing's disease: transsphenoidal selective adenomectomy by an experienced pituitary surgeon is first-line.
• Adrenal adenoma or carcinoma: laparoscopic (adenoma) or open (carcinoma) adrenalectomy; mitotane is used adjunctively in adrenocortical carcinoma.
• Ectopic ACTH: resect the source tumor when localized and resectable.
• Remission marker: a post-operative morning serum cortisol below roughly 2 mcg/dL with clinical adrenal insufficiency predicts cure — patients require glucocorticoid replacement (hydrocortisone) until the suppressed HPA axis recovers, often 6–12 months.

Medical therapy — for persistent, recurrent, occult-ectopic, or preoperative disease

• Steroidogenesis inhibitors: osilodrostat, metyrapone (both 11β-hydroxylase inhibitors), ketoconazole/levoketoconazole, mitotane.
• Pituitary-directed agents: pasireotide (somatostatin analog) and cabergoline (dopamine agonist) for Cushing's disease.
• Glucocorticoid receptor antagonist: mifepristone, useful when hyperglycemia dominates; cortisol levels rise on therapy, so it must be titrated clinically, not biochemically.

Contraindications and cautions

• Mifepristone is absolutely contraindicated in pregnancy (abortifacient).
• Ketoconazole: hepatotoxicity, QT prolongation, extensive CYP interactions.
• Never stop exogenous glucocorticoids abruptly in iatrogenic disease — taper slowly to avoid adrenal crisis.

Complications of the disease

• Venous thromboembolism: cortisol upregulates factor VIII, von Willebrand factor, and PAI-1 while impairing fibrinolysis; sudden dyspnea and hypoxemia after surgery signal pulmonary embolism — an emergency.
• Cardiovascular disease: accelerated atherosclerosis, LV hypertrophy, and resistant hypertension; myocardial infarction and stroke are the leading causes of death.
• Opportunistic and occult infection: suppressed cell-mediated immunity plus blunted fever/leukocyte response means sepsis presents late; Pneumocystis, tuberculosis reactivation, and invasive fungal disease are the classic organisms — emergency.
• Osteoporosis and vertebral compression fracture: reduced osteoblast function with increased resorption; painless loss of height or a wedge fracture on incidental imaging is the signal. Avascular necrosis of the femoral head presents as groin pain with normal early radiographs.
• Metabolic: diabetes, dyslipidemia, hypokalemic metabolic alkalosis (cortisol saturating 11β-HSD2), nephrolithiasis from hypercalciuria.
• Psychiatric: depression, mania, and frank psychosis; suicidality is an emergency.

Complications of treatment

• Post-operative adrenal insufficiency / adrenal crisis: the expected consequence of cure, since the contralateral or non-tumorous corticotrophs are suppressed. Hypotension refractory to fluids, hyponatremia, hypoglycemia, and abdominal pain demand immediate IV hydrocortisone and fluids — an emergency.
• Glucocorticoid withdrawal syndrome: arthralgias, malaise, and mood disturbance despite adequate replacement, reflecting receptor downregulation.
• Transsphenoidal surgery: transient diabetes insipidus, delayed hyponatremia around the end of the first post-operative week, CSF rhinorrhea with risk of meningitis, and hypopituitarism.
• Nelson syndrome after bilateral adrenalectomy: loss of feedback drives corticotroph tumor growth — progressive hyperpigmentation, very high ACTH, and visual field loss from mass effect.
• Drug-specific: metyrapone and osilodrostat cause 11-deoxycorticosterone accumulation with hypokalemia, hypertension, and hirsutism; ketoconazole causes hepatotoxicity; pasireotide causes marked hyperglycemia; mifepristone causes endometrial thickening, hypokalemia, and adrenal insufficiency that cannot be tracked by cortisol levels.

• The most common cause overall is exogenous glucocorticoid: expect low ACTH and low cortisol, bilaterally small adrenals, and no hyperpigmentation. Endogenous causes are the exception, and Cushing's disease is the most common of those.
• The single best next step after two abnormal screening tests is plasma ACTH — not imaging. Imaging before biochemistry is the classic wrong answer, because incidentalomas are common in both pituitary and adrenal glands.
• Suppression on high-dose (8 mg) dexamethasone favors a pituitary adenoma; ectopic ACTH tumors do not suppress and do not respond to CRH. When MRI is negative or the lesion is tiny, the answer is inferior petrosal sinus sampling.
• Ectopic ACTH buzzwords: rapid onset, weight loss, profound proximal weakness, hyperpigmentation, and severe hypokalemic metabolic alkalosis in a smoker — think small-cell lung cancer. Cortisol is high enough to overwhelm renal 11β-HSD2, letting cortisol act at the mineralocorticoid receptor.
• The most discriminating physical findings are proximal myopathy, wide violaceous striae (>1 cm), easy bruising, and facial plethora — not central obesity, which is nonspecific.
• Pseudo-Cushing is the favorite distractor: alcohol use disorder, major depression, and poorly controlled diabetes can produce abnormal cortisol dynamics that normalize with abstinence or treatment.
• Post-operative adrenal insufficiency signals cure, not failure. A patient hypotensive and hyponatremic days after transsphenoidal surgery needs stress-dose hydrocortisone, and the HPA axis may take months to recover.
• Association most tested: bilateral adrenalectomy → Nelson syndrome (rising ACTH, hyperpigmentation, sellar mass). A second association worth knowing is PRKAR1A mutation → primary pigmented nodular adrenocortical disease within Carney complex.